Related references
Note: Only part of the references are listed.Screening for Type 2 Diabetes Mellitus: A Systematic Review for the US Preventive Services Task Force
Shelley Selph et al.
ANNALS OF INTERNAL MEDICINE (2015)
Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance
Harsha Tella et al.
THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM (2015)
Classification and Diagnosis of Diabetes
[Anonymous]
DIABETES CARE (2015)
Increase in Visceral Fat Per Se Does Not Induce Insulin Resistance in the Canine Model
Ana V. B. Castro et al.
OBESITY (2015)
High-Fat Diet-Induced Insulin Resistance Does Not Increase Plasma Anandamide Levels or Potentiate Anandamide Insulinotropic Effect in Isolated Canine Islets
Orison O. Woolcott et al.
PLOS ONE (2015)
Hepatic portal vein denervation impairs oral glucose tolerance but not exenatide's effect on glycemia
Viorica Ionut et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2014)
The effect of chronic twice daily exenatide treatment on β-cell function in new onset type 2 diabetes
Amalia Gastaldelli et al.
CLINICAL ENDOCRINOLOGY (2014)
Mechanism of the beneficial and protective effects of exenatide in diabetic rats
Mohamed Lotfy et al.
JOURNAL OF ENDOCRINOLOGY (2014)
Hepatic Insulin Clearance Is the Primary Determinant of Insulin Sensitivity in the Normal Dog
Marilyn Ader et al.
OBESITY (2014)
Incretin Action in the Pancreas: Potential Promise, Possible Perils, and Pathological Pitfalls
Daniel J. Drucker
DIABETES (2013)
The glucagon-like peptide-1 receptor agonist exenatide restores impaired pro-islet amyloid polypeptide processing in cultured human islets: implications in type 2 diabetes and islet transplantation
Y. J. Park et al.
DIABETOLOGIA (2013)
Alterations in energy balance following exenatide administration
David P. Bradley et al.
APPLIED PHYSIOLOGY NUTRITION AND METABOLISM-PHYSIOLOGIE APPLIQUEE NUTRITION ET METABOLISME (2012)
Effects of Exenatide vs. Metformin on endothelial function in obese patients with pre-diabetes: a randomized trial
Aaron S. Kelly et al.
CARDIOVASCULAR DIABETOLOGY (2012)
Anti-Inflammatory Properties of Exenatide in Human Pancreatic Islets
S. R. Cechin et al.
CELL TRANSPLANTATION (2012)
SUCCESSFUL TREATMENT OF PREDIABETES IN CLINICAL PRACTICE: TARGETING INSULIN RESISTANCE AND β-CELL DYSFUNCTION
John Armato et al.
ENDOCRINE PRACTICE (2012)
Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial
Baptist Gallwitz et al.
LANCET (2012)
Simplified Method to Isolate Highly Pure Canine Pancreatic Islets
Orison O. Woolcott et al.
PANCREAS (2012)
Incretin Effects on β-cell Function, Replication, and Mass The human perspective
Alan J. Garber
DIABETES CARE (2011)
Single dose streptozotocin-induced diabetes: considerations for study design in islet transplantation models
M. C. Deeds et al.
LABORATORY ANIMALS (2011)
Epidemiology of Prediabetes
Stephen Colagiuri
MEDICAL CLINICS OF NORTH AMERICA (2011)
Consistency of the Disposition Index in the Face of Diet Induced Insulin Resistance: Potential Role of FFA
Darko Stefanovski et al.
PLOS ONE (2011)
Divergent effects of GLP-1 analogs exendin-4 and exendin-9 on the expression of myosin heavy chain isoforms in C2C12 myotubes
Lina Wang et al.
PEPTIDES (2011)
Detailed protocol for evaluation of dynamic perifusion of human islets to assess β-cell function
Kwamina Bentsi-Barnes et al.
ISLETS (2011)
Novel canine models of obese prediabetes and mild type 2 diabetes
Viorica Ionut et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2010)
Effects of Exenatide Plus Rosiglitazone on β-Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes on Metformin
Ralph A. DeFronzo et al.
DIABETES CARE (2010)
Prevalence, Diagnosis, and Treatment of Impaired Fasting Glucose and Impaired Glucose Tolerance in Nondiabetic US Adults
Amrita Karve et al.
DIABETES CARE (2010)
Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-Diabetes
Julio Rosenstock et al.
DIABETES CARE (2010)
Rimonabant prevents additional accumulation of visceral and subcutaneous fat during high-fat feeding in dogs
Joyce M. Richey et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2009)
Pathophysiology of prediabetes
Muhammad A. Abdul-Ghani et al.
CURRENT DIABETES REPORTS (2009)
Exenatide Sensitizes Insulin-Mediated Whole-Body Glucose Disposal and Promotes Uptake of Exogenous Glucose by the Liver
Dan Zheng et al.
DIABETES (2009)
Effects of exendin-4 on islets from type 2 diabetes patients
R. Lupi et al.
DIABETES OBESITY & METABOLISM (2008)
The Role of Incretins in Glucose Homeostasis and Diabetes Treatment
Wook Kim et al.
PHARMACOLOGICAL REVIEWS (2008)
The physiology of glucagon-like peptide 1
Jens Juul Holst
PHYSIOLOGICAL REVIEWS (2007)
Impaired fasting glucose and impaired glucose tolerance - Implications for care
David M. Nathan et al.
DIABETES CARE (2007)
Arachidonic acid is a physiological activator of the ryanodine receptor in pancreatic β-cells
Orison O. Woolcott et al.
CELL CALCIUM (2006)
Pioglitazone - A review of its use in type 2 diabetes mellitus
J Waugh et al.
DRUGS (2006)
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea
DM Kendall et al.
DIABETES CARE (2005)
Exenatide (Exendin-4) improves insulin sensitivity and β-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight
BR Gedulin et al.
ENDOCRINOLOGY (2005)
Exendin-4 increases insulin sensitivity via a PI-3-kinase-dependent mechanism: contrasting effects of GLP-1
I Idris et al.
BIOCHEMICAL PHARMACOLOGY (2002)
Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro
DG Parkes et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2001)
Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type a diabetes development
C Weyer et al.
DIABETES CARE (2001)
Share Paper
